MiMedx Group (NASDAQ: MDXG)
MiMedx Group Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MiMedx Group Company Info
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
News & Analysis
Why Shares of MiMedx Are Collapsing Today
The company released data for two drug programs and missed its goals on both.
Here's Why MiMedx Group Shares Are Imploding 30% Today
The company's shares are being delisted from the Nasdaq exchange tomorrow.
Here's Why MiMedx Group, Inc. Gained 16.6% in September
A C-suite sweep and good news from a major market exchange lifted the troubled biotech stock.
Here's Why MiMedx Group Inc. Rose 24.7% in August
The company announced product updates and earned an extension to remain listed on the Nasdaq exchange -- for now.
Why Dillard's, MiMedx Group, and Global Net Lease Slumped Today
Find out which of these stocks fared the worst on an positive day for the market.
Yet Another Setback Caused MiMedx Group Shares to Tumble Today
An insurer is saying it will no longer reimburse for the use of MiMedx products.
Here's Why MiMedx Group Inc. Stock Is Falling Today
The biopharma is perilously close to being delisted from the Nasdaq stock exchange.
Why MiMedx Group Shares Skyrocketed 18% Today
The hope that a C-suite shake-up and restated financials will put the company's worst days behind it are fueling a rally.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.